

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Yutaro KANEKO, et al.

SERIAL NO: 09/087,513

GAU: 1632

FILED: May 29, 1998

EXAMINER: M. WILSON

FOR: ALTERED ENVELOPE GLYCOPROTEIN FOR HIV VACCINE AND TREATMENT OF PATIENTS WITH HIV INFECTION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached European Office Action and Form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

James J. Kelly

Registration No. 41,504

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

0010-0929-0X

SERIAL NO.

09/087,513

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Yutaro KANEKO, et al.

FILING DATE

May 29, 1998

GROUP

1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	WO 97/24447	07/10/97	WIPO		
	AP	WO 94/22477	10/13/94	WIPO		
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	Journal of Virology, vol. 66, No. 12, Dec. 1, 1992, pp. 6997-7004, Richard Wyatt, et al., "RELATIONSHIP OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp120 THIRD VARIABLE LOOP TO A COMPONENT OF THE CD4 BINDING SITE IN THE FOURTH CONSERVED REGION", XP000579276 ISSN: 0022-538X.	
	AX	C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences, 1996, vol. 319, No. 11, pp. 983-990, Claude Lavallee, et al., "ENGINEERING, EXPRESSION AND CHARACTERIZATION OF HIV-1 gp160 PARTIALLY OR COMPLETELY DELETED IN THE V3 LOOP", XP002155492 ISSN: 0764-4469.	
	AY	Journal of Virology, vol. 67, No. 11, Nov. 1993, pp. 6897-6902, Nicole K. T. Back, et al., "MUTATIONS IN HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 gp41 AFFECT SENSITIVITY TO NEUTRALIZATION BY gp120 ANTIBODIES"	
	AZ	Sarah L. Rowland-Jones, et al., Immunology Letters, 1999, pp. 9-14, "BROADLY CROSS-REACTIVE HIV-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IN HIGHLY EXPOSED PERSISTENTLY SERONEGATIVE DONORS"	<input checked="" type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

SERIAL NO.

0010-0929-0X

09/087,513

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Yutaro KANEKO, et al.

FILING DATE

May 29, 1998

GROUP

1632

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AAA	Irena Kiszka, et al., Journal of Virology, May 2002, pp. 4222-4232, "EFFECT OF THE V3 LOOP DELETION OF ENVELOPE GLYCOPROTEIN ON CELLULAR RESPONSES AND PROTECTION AGAINST CHALLENGE WITH RECOMBINANT VACCINIA VIRUS EXPRESSING gp160 OF PRIMARY HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ISOLATES"
	AAB	Dariusz Kmiecik, et al., The Journal of Immunology, 1998, vol. 160, pp. 5676-5683, "THE EFFECT OF DELETION OF THE V3 LOOP OF gp120 ON CYTOTOXIC T CELL RESPONSES AND HIV gp120-MEDIATED PATHOGENESIS"
	AAC	
	AAD	
	AAE	
	AAF	
	AAG	
	AAH	
	AAI	
	AAJ	
	AAK	
	AAL	
	AAM	
	AAN	
	AAO	
	AAP	
	AAQ	

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.